Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
Authors
Keywords
Niclosamide, PD-L1, STAT3, Immunotherapy, NSCLC
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-11
DOI
10.1186/s40425-019-0733-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects
- (2019) Long Long et al. CLINICAL DRUG INVESTIGATION
- Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial
- (2018) Susen Burock et al. BMC CANCER
- Niclosamide: Beyond an antihelminthic drug
- (2018) Wei Chen et al. CELLULAR SIGNALLING
- Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy
- (2018) Bao-Dong Qin et al. MEDICAL HYPOTHESES
- A Landscape of Metabolic Variation across Tumor Types
- (2018) Ed Reznik et al. Cell Systems
- Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers
- (2018) R. Kumar et al. Nature Communications
- Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
- (2018) Hongshu Sui et al. Journal of Immunology Research
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
- (2017) V Atsaves et al. LEUKEMIA
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- The role of STAT3 in tumor-mediated immune suppression
- (2015) Sherise D. Ferguson et al. JOURNAL OF NEURO-ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
- (2014) Yonghe Li et al. CANCER LETTERS
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells
- (2013) Atish Patel et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Expression of ERBB3 binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its clinicopathological relevance
- (2012) Jian Sun et al. BMC CANCER
- Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity
- (2012) F. Cheng et al. CANCER RESEARCH
- Re: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Samir S. Taneja JOURNAL OF UROLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
- (2010) Chuan-Yong Mu et al. MEDICAL ONCOLOGY
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer
- (2008) Martin Loos et al. CANCER LETTERS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now